Literature DB >> 10928135

Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma.

D L Persons1, D A Arber, J A Sosman, K A Borelli, M L Slovak.   

Abstract

The HER-2/neu proto-oncogene is a useful prognostic and predictive biomarker in breast cancer. In addition, use of a humanized monoclonal antibody against HER-2/neu has recently been shown to have efficacy in the treatment of metastatic breast cancer. In order to examine the potential of HER-2/neu as a biomarker and as a target for HER-2/neu monoclonal antibody treatment in melanoma, we examined the HER-2/neu status in 40 advanced stage melanomas. Using fluorescence in situ hybridization for determining the gene amplification status and immunohistochemistry for detecting protein overexpression, we found that only one out of 40 cases of melanoma had an altered HER-2/neu status. These results demonstrated that HER-2/neu amplification and overexpression are not common in advanced stage melanoma and thus, HER-2/neu would have limited value as a biomarker or as a target for immunotherapy in melanoma.

Entities:  

Mesh：

Year:  2000        PMID： 10928135

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  9 in total

1.  Quantitative analysis of surface plasma membrane proteins of primary and metastatic melanoma cells.

Authors:  Haibo Qiu; Yinsheng Wang
Journal:  J Proteome Res       Date:  2008-04-15       Impact factor: 4.466

2.  Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.

Authors:  Bonnie E Gould Rothberg; David L Rimm
Journal:  J Invest Dermatol       Date:  2010-06-17       Impact factor: 8.551

3.  Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma.

Authors:  Anil Potti; Nauman Moazzam; Eric Langness; Kaley Sholes; Ketki Tendulkar; Michael Koch; Steve Kargas
Journal:  J Cancer Res Clin Oncol       Date:  2003-11-21       Impact factor: 4.553

4.  Anatomic site-specific patterns of gene copy number gains in skin, mucosal, and uveal melanomas detected by fluorescence in situ hybridization.

Authors:  Katharina Glatz-Krieger; Mona Pache; Coya Tapia; Alain Fuchs; Spasenija Savic; Dieter Glatz; Michael Mihatsch; Peter Meyer
Journal:  Virchows Arch       Date:  2006-03-08       Impact factor: 4.064

5.  Expression and amplification of therapeutic target genes in retinoblastoma.

Authors:  Doris Bösch; Mona Pache; Ronald Simon; Peter Schraml; Katharina Glatz; Martina Mirlacher; Josef Flammer; Guido Sauter; Peter Meyer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-11-10       Impact factor: 3.117

6.  HER2 as a promising target for cytotoxicity T cells in human melanoma therapy.

Authors:  Juan Ma; Huamin Han; Deruo Liu; Wei Li; Hongxiang Feng; Xin Xue; Xiaoran Wu; Ge Niu; Ge Zhang; Yunfeng Zhao; Changzhen Liu; Hua Tao; Bin Gao
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

7.  Generating CAR T cells from tumor-infiltrating lymphocytes.

Authors:  Jane K Mills; Melissa A Henderson; Lauren Giuffrida; Pasquale Petrone; Jennifer A Westwood; Phillip K Darcy; Paul J Neeson; Michael H Kershaw; David E Gyorki
Journal:  Ther Adv Vaccines Immunother       Date:  2021-05-31

8.  Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment.

Authors:  Yuen-Keng Ng; Jia-Ying Lee; Kathryn M Supko; Ayesha Khan; Salina M Torres; Marianne Berwick; Jonhan Ho; John M Kirkwood; Jill M Siegfried; Laura P Stabile
Journal:  Melanoma Res       Date:  2014-06       Impact factor: 3.199

9.  Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications.

Authors:  Anil Potti; Rachel C Hille; Michael Koch
Journal:  J Carcinog       Date:  2003-11-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.